Zealand Pharma A/S (OTCMKTS:ZLDPF) Downgraded to “Hold” Rating by Barclays

Barclays downgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Free Report) from a strong-buy rating to a hold rating in a research report report published on Tuesday,Zacks reports.

ZLDPF has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Zacks Research cut shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a report on Thursday, August 13th. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Finally, Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Get Zealand Pharma A/S alerts:

Read Our Latest Report on ZLDPF

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock opened at $46.38 on Tuesday. Zealand Pharma A/S has a 12 month low of $35.93 and a 12 month high of $83.12. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a market cap of $3.32 billion, a P/E ratio of 7.69 and a beta of 0.89. The firm has a fifty day moving average price of $47.47 and a 200 day moving average price of $47.39.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

Read More

• Five stocks we like better than Zealand Pharma A/S
• Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
• Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
• Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
• Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.